These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29237919)

  • 21. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer.
    Zhao L; Wang J; Li H; Che J; Cao B
    Oncotarget; 2016 May; 7(22):33418-28. PubMed ID: 27072579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
    J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
    Zhou M; Yu P; Qu X; Liu Y; Zhang J
    PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study.
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Clin Colorectal Cancer; 2016 Dec; 15(4):e165-e174. PubMed ID: 27256668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing the efficacy of first-line chemotherapy plus bevacizumab in metastatic colorectal cancer: analysis of multiple methods.
    Li S; Chi P
    BioDrugs; 2011 Feb; 25(1):43-50. PubMed ID: 21080747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
    Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
    Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group.
    Tahover E; Hubert A; Temper M; Salah A; Peretz T; Hamburger T; Uziely B
    Target Oncol; 2015 Mar; 10(1):55-63. PubMed ID: 24599713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
    Cunningham D; Lang I; Marcuello E; Lorusso V; Ocvirk J; Shin DB; Jonker D; Osborne S; Andre N; Waterkamp D; Saunders MP;
    Lancet Oncol; 2013 Oct; 14(11):1077-1085. PubMed ID: 24028813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
    Ye Q; Chen HL
    Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.
    Sanna G; Fabi A; Crivellari D; Saracchini S; Battelli N; Nisticò C; Capobianco AM; Zampa G; Bottini A; Del Prete S; Simoncini E; Galli A; Matasconi M; Restuccia E; Biganzoli L
    Tumori; 2014; 100(4):432-8. PubMed ID: 25296593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.